Introduction {#sec1_1}
============

Alzheimer\'s disease (AD) is a progressive neurodegenerative disease and the most common cause of dementia \[[@B1]\]. The main neuropathological changes associated with AD are extracellular accumulation of amyloid-β plaques, intracellular accumulation of neurofibrillary tangles of τ protein, inflammation, and brain atrophy \[[@B1]\]. Unfortunately, no cure currently exists for AD. Recent studies have shown that brain changes associated with AD start more than a decade before the onset of clinical symptoms such as progressive memory deficits \[[@B2], [@B3], [@B4], [@B5]\]. Thus, in order to reduce the incidence and prevalence of AD, it will be necessary to focus on the stage before clinical symptoms appear \[[@B6]\]. Accumulating evidence suggests that systemic metabolic dysfunction such as diabetes, vascular dysfunction, and systemic inflammation underlie the development of AD \[[@B7], [@B8], [@B9]\]. These systemic changes also precede the onset of clinical symptoms of the disease. The discovery of a panel of biomarkers that reflect these systemic changes and could therefore predict the development of AD would be valuable for screening those at risk.

Urine is one of the most preferred biofluids for biomarker discovery because urine collection is simple and noninvasive. Moreover, repeated urine sampling from the same individual is easy, as is collection of a sufficient volume for analysis compared to other biofluids \[[@B10], [@B11]\]. Urine also contains systemic information since approximately 30% of urinary protein originates from plasma via blood filtration, with the remainder coming from the kidneys and the urinary tract \[[@B10], [@B12]\]. With technological advances in mass spectrometry (MS), MS-based proteomics has been used to identify a large number of proteins belonging to the urinary proteome \[[@B11], [@B13]\]. While the discovery of predictive biomarkers for AD from urine would be highly beneficial, information regarding biological and pathophysiological changes in the urine of AD patients is currently limited. In the present study, urinary proteomes of AD patients and cognitively normal elderly controls were compared to explore the comprehensive profile and molecular-network relations of the urinary proteome of AD patients.

Materials and Methods {#sec1_2}
=====================

Participants and Classification {#sec2_1}
-------------------------------

AD patients were recruited from outpatients of Niigata University Hospital who were diagnosed with the disease based on criteria of the National Institute of Neurological and Communicative Disorders and Stroke AD and Related Disorders Association (NINCDS-ADRDA) and took the Mini-Mental State Examination (MMSE) \[[@B14]\] within a year of urine collection. The clinical characteristics of the AD group are summarized in online supplementary Table 1 (for all online suppl. material, see [www.karger.com/doi/10.1159/000496100](http://www.karger.com/doi/10.1159/000496100)).

Age- and sex-matched cognitively normal controls (MMSE score \> 27) were selected from a subcohort (Sekikawa cohort) of the Murakami cohort, a population-based cohort study that targeted individuals aged between 40 and 74 years living in areas of the northern Niigata Prefecture (Murakami region) \[[@B15]\]. Participants provided urine samples at specific health checkups held by the national health insurance of Japan and underwent the MMSE within a year of urine collection.

Urine Sample Collection and Laboratory Test {#sec2_2}
-------------------------------------------

Spot urine samples were obtained from participants. No restrictions on diet, drinking, or exercise were required prior to urine sampling. Urinary protein, urinary sugar, and occult blood were checked using urine test strips (Pretest 5bII \[Wako, Japan\] for AD samples and Hema-Combistix-long \[Siemens Healthcare, Japan\] for control samples). Urinary albumin and creatinine were measured by latex immunological nephelometry using a SPOTCHEM D-01 analyzer (SD-3810; Arkray Global Business, Inc. Japan). Urine samples were centrifuged at 1,000 *g* for 15 min and the supernatant was stored at −20°C until use.

MS and Semiquantification of Proteome Data {#sec2_3}
------------------------------------------

Detailed methods for protein extraction, MS analysis, and semiquantification of proteome data can be found in the online supplementary material. In brief, urine proteins were precipitated by the methanol precipitation method, dissolved, and digested in solution by trypsin. Digested samples were purified using a C18 spin column and peptides (500 ng) were analyzed by liquid chromatography coupled to tandem MS (MS/MS). All MS and MS/MS spectrums were analyzed by MASCOT (v4.2; Matrix Science) for protein and peptide identification. Data were queried against the Uniprot/Swiss-Prot database. Identification of proteins and peptides was carried out with a significance threshold of *p* \< 0.05. The normalized spectral index (SI~N~), a label-free quantification method \[[@B16]\], was used to compare protein abundance between different samples.

Bioinformatics Analysis {#sec2_4}
-----------------------

Gene enrichment analysis was performed using functional annotation clustering of DAVID Bioinformatics Resources 6.8 (<https://david.ncifcrf.gov/home.jsp>) \[[@B17], [@B18]\]. Molecular network analysis was performed using KeyMolnet software (KM Data, Tokyo, Japan) \[[@B19]\]. Details of the KeyMolnet analysis are provided in the online supplementary material.

Statistical Analysis {#sec2_5}
--------------------

Statistical analysis was performed using SAS® Studio 3.7 software (SAS Institute Inc., Cary, NC, USA). Means of protein abundance were compared using a *t* test with Welch\'s correction (α = 0.05). Pearson\'s ρ (r) was used to assess expression-level correlations of proteins among and between AD and control groups. Multiple comparisons were accounted for by using a false discovery rate adjustment (q = 0.05). Graphs were prepared using GraphPad software (GraphPad Prism version 7.0a for Mac; La Jolla, CA, USA).

Results {#sec1_3}
=======

Protein Identification by Liquid Chromatography-MS/MS and Semiquantification by SI~N~ {#sec2_6}
-------------------------------------------------------------------------------------

Urine samples were collected from 18 AD patients (8 males and 10 females) and 18 cognitively normal (MMSE \> 27 points) controls selected from participants of the Murakami cohort in an age- and sex-matched manner. General characteristics of the participants and the results of general urinalysis are shown in Table [1](#T1){ref-type="table"}.

For AD and control urine samples, 613.2 ± 117.7 and 589.7 ± 87.3 (mean ± SD) proteins were identified, respectively. Of the total of 1,705 unique proteins identified, 382 and 160 proteins were uniquely identified in AD and control groups, respectively, and 1,163 proteins were shared between the 2 groups (Fig. [1a](#F1){ref-type="fig"}). For further analysis, 578 proteins identified in at least 9 samples of either group, excluding 28 keratin isoforms, were selected. Of these, 71 and 37 proteins were uniquely identified in AD and control groups, respectively, and 470 proteins were shared between the 2 groups (Fig. [1b](#F1){ref-type="fig"}). To estimate protein abundance, SI~N~, a label-free quantification method, was used. Proteins that were not identified in certain samples were assumed to be at levels under the detection limit and thus they were assigned a value that was half of the minimum SI~N~ value (i.e., 0.0001).

Welch\'s *t* test identified 73 proteins that were significantly increased by more than 2-fold and 36 proteins that were significantly decreased by less than 0.5-fold in the AD group compared to the control group (Fig. [1c](#F1){ref-type="fig"}). The accession numbers, names, logarithm of the fold change ratio (AD/control) of the average SI~N~ values, and molecular weights of proteins that were significantly increased or decreased are listed in Table [2](#T2){ref-type="table"}. Twenty-four proteins remained significant after false discovery rate correction (bold in Table [2](#T2){ref-type="table"}).

The expression-level correlations of proteins listed in Table [2](#T2){ref-type="table"} were analyzed in the AD group and the control group (online suppl. Tables 2A and B). Correlations were compared between AD and control groups (online suppl. Table 2C). Eleven correlations involving proteins (PSAP, RDX, C7, CPVL, LAIR1, GAA, GALNS, BGN, CNTN1, GPRC5C, and MAN1A1) were significant in both the AD group and the control group (online suppl. Table 2D), and 4 proteins (PSAP, GAA, GALNS, and BGN) were annotated to the lysosome.

Bioinformatics Analysis {#sec2_7}
-----------------------

To provide a broad overview of the identified proteins in each group, gene ontology (GO) analysis was performed using DAVID. The profiles of both groups had very similar distributions of GO annotations (online suppl. Fig. 1). To assess the functional significance of significantly increased or decreased proteins in the AD group, functional annotation clustering analysis with DAVID was performed using the GO database and KEGG pathway. Three annotation clusters related to lysosomes, complement activation, and gluconeogenesis were significantly enriched (Table [3](#T3){ref-type="table"}; online suppl. Fig. 2).

To identify relationships between the molecular network of the urinary proteome and canonical pathway, an "interrelation" network search was performed using KeyMolnet. In the extracted molecular network, 18 pathways scored \> 20 and significantly contributed to the extracted network (online suppl. Table 3). The 5 pathways with the highest scores were the heat shock protein (HSP) 90 signaling pathway (score 104.424), lipoprotein metabolism (score 86.737), redox regulation by thioredoxin (score 53.188), the matrix metalloproteinase (MMP) signaling pathway (score 45.325), and the tetraspanin signaling pathway (score 45.319) (Table [4](#T4){ref-type="table"}, upper panel). To extract molecular relations between AD-related molecules and the urinary proteome, a "start points and end points" network search was performed using KeyMolnet. We found that 71 proteins which were significantly increased or decreased in the urine proteome were associated with AD-related molecules directly or via an inter­mediate molecule (online suppl. Fig. 4), and 12 pathways significantly contributed to the extracted AD-related network (online suppl. Table 4). Of the 12 pathways, 4 of the top 5 were also listed among the top 5 pathways determined in the "interrelation" network search, i.e., lipoprotein metabolism (score 90.350), the HSP90 signaling pathway (score 57.456), the MMP signaling pathway (score, 47.188), and redox regulation by thioredoxin (score 44.021) (Table [4](#T4){ref-type="table"}, lower panel).

Discussion {#sec1_4}
==========

With recent advances in MS-based proteomics, urine has been used in biomarker studies of various diseases, not limited to renal and urogenital diseases, but also for non­urogenital diseases such as diabetes, osteoarthritis, cardiovascular disease, lung cancer, and other types of cancer \[[@B11], [@B20], [@B21], [@B22], [@B23], [@B24], [@B25], [@B26], [@B27], [@B28], [@B29], [@B30]\]. Many AD biomarker studies have used a proteomics approach, with most using CSF and blood but only a few using urine \[[@B31], [@B32]\]. A comprehensive profile of the urinary proteome is important for urine biomarker discovery \[[@B11], [@B13]\]. Therefore, in this study, we performed MS-based urine proteomics with label-free quantification, which offers a greater dynamic range and a wider proteome coverage compared to label-based methods \[[@B11]\], in order to gain a comprehensive view of the urinary proteome of AD patients.

In this study, we compared the urinary proteome of 18 AD patients and 18 age- and sex-matched cognitively normal elderly individuals. The average number of identified proteins in individual urine samples was 613 and 589 in the AD and control groups, respectively. This is comparable to previous reports \[[@B13], [@B33], [@B34]\]. Recent studies have found that systemic changes, such as insulin resistance, atherosclerosis, and increased inflammation underlie the development of AD \[[@B7], [@B8], [@B9]\]. Among the proteins significantly increased or decreased in the AD group compared to the control group, proteins related to lysosomes, the complement pathway, and gluconeogenesis were enriched. In the molecular network analysis, canonical pathways of lipoprotein metabolism, HSP90 signaling, MMP signaling, and redox regulation by thioredoxin significantly contributed to the molecular network of the urinary proteome and AD- related molecules.

Lysosomes are major cellular organelles that digest and recycle all types of intracellular macromolecules and thus play a major role in protein homeostasis \[[@B35]\]. Previous studies have suggested the involvement of impaired lysosomal activity, including lysosomal enzyme malfunction, in the AD brain starting from an early stage of the disease \[[@B36], [@B37], [@B38], [@B39]\]. In the present study, 7 of 11 lysosome-related proteins corresponded to lysosomal hydrolase. Previous studies have also reported increased activity of lysosomal glycohydrolases at the peripheral level in AD patients \[[@B40], [@B41]\].

Although most lysosome-related proteins were increased in AD urine, cathepsin L1 (CTSL) was not. Cathepsins are the most abundant lysosomal proteases and they have been implicated in neuronal death in AD patients \[[@B42]\]. Interestingly, CTSL activity is inhibited in the brains of aged animals \[[@B43]\]. Moreover, recent studies have found that CTSL functions as a key protease for the proteolytic processing of proneuropeptides into active neurotransmitters, and thus it is required for normal neurotransmission \[[@B44]\].

The complement system represents a key inflammatory pathway for the activation and execution of immune responses. Inflammatory responses in the brain are characteristic of AD pathology \[[@B45], [@B46]\]. Recent studies have also revealed the occurrence of peripheral or systemic inflammation early in the development of AD \[[@B47], [@B48]\].

Insulin is a key hormone that inhibits gluconeogenesis, and insulin resistance is a hallmark of type 2 diabetes \[[@B49]\]. Type 2 diabetes can cause mitochondrial dysfunction and promote an inflammatory response similar to that which triggers AD \[[@B50]\]. Epidemiological studies have found that the risk of AD is about 1.5-fold higher among people with diabetes than in the general population \[[@B51], [@B52]\]. In the current study, we did not have sufficient information regarding the diabetic status of our participants, particularly the control group. However, the enrichment of proteins related to gluconeogenesis in the urine of AD patients is consistent with the known relationship between AD and diabetes.

Another protein listed in Table [2](#T2){ref-type="table"} that might participate in glucose metabolism is insulin-like growth factor-binding protein-3 (IGFBP3). IGFBP3 is a major binding protein of IGF-1 and several studies have reported its association with incident diabetes \[[@B53], [@B54]\]. Although results are inconsistent, alterations of circulating IGFBP3 levels in AD patients have been reported \[[@B55], [@B56]\].

Several recent studies have concluded that intrabrain vascular dysregulation is the earliest and strongest pathologic factor associated with late-onset AD \[[@B8], [@B57]\]. Atherosclerosis is a leading cause of vascular dysfunction, and it is the result of hyperlipidemia and lipid oxidation \[[@B8], [@B58]\]. Thioredoxin is a major regulator of the cellular redox system that protects various cells from oxidative stress and is involved in atherogenesis \[[@B59]\]. According to one study, patients with atherosclerosis had an increased level of plasma thioredoxin-1 \[[@B60]\]. MMP are a large family of proteolytic enzymes and they have been implicated in the development and progression of atherosclerosis \[[@B61]\]. HSP90 is a molecular chaperone that prevents protein misfolding and aggregation \[[@B62]\]. HSP90 and HSP70 have been shown to exert their effects on atherosclerosis by influencing LDL metabolism, and the expression of HSP90 in atherosclerotic plaques has been associated with plaque instability \[[@B63]\].

Another vascular related protein that was significantly increased in AD urine is oxidized low-density lipoprotein receptor 1 (OLR1), which is also known as lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1). OLR1/LOX-1 is a marker for atherosclerosis and it is induced by oxidative stress, inflammatory cytokines, and oxidized low-density lipoprotein \[[@B64]\]. Several studies have suggested an association of several SNP within OLR1 with AD \[[@B65]\].

Expression levels of several proteins in AD urine observed in the present study were inconsistent with previous reports. For example, S100A6 was significantly decreased in AD urine. In the brain, however, S100A6 has been reported to be upregulated in astrocytes of amyotrophic lateral sclerosis patients and in AD patients \[[@B66]\].

Although some studies have reported that hyperlipidemia is associated with AD pathogenesis, APOC3 was significantly decreased in AD urine. APOC3 is a major component of triglyceride-rich lipoproteins (chylomicrons and very low-density lipoprotein) and a minor component of high-density lipoprotein. Lin et al. \[[@B67]\] reported decreased levels of serum APOC3 with the progression of AD. Recent studies have reported that weight loss is a predictor of AD and may be related to the hypothalamic defects observed in AD patients \[[@B68], [@B69]\].

The present study has some limitations worth noting. First, the abundance of urinary proteins was estimated via a semiquantitative method and requires further validation by a quantitative method. Second, information regarding the comorbidities and renal function of participants was limited. Third, this study employed a cross-sectional case-control design. Further validation of our findings with a larger sample size and different populations is warranted. The above information notwithstanding, we were able to demonstrate differences in the urinary proteome of AD patients compared to cognitively normal controls and that the urinary proteome of AD patients reflects systemic changes that underlie AD pathophysiology. Further studies targeting earlier-stage AD patients or population-based pro spective studies will help to clarify the potential of urine as a source of biomarkers for early screening of AD.
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![Venn diagrams of all of the identified proteins (**a**) and proteins identified in at least 9 samples of either group (**b**). **c** Volcano plot displaying differentially expressed proteins between the AD and control groups. The *x*-axis displays the log 2-fold change (FC) of the mean SI~N~ value between the groups, while the *y*-axis corresponds to the absolute value of log 10 (*p* value) of the *t* test with Welch\'s correction. Closed black circles represent the 73 increased proteins in the AD group (FC \> 2, *p* \< 0.05) and open circles represent the 36 decreased proteins in the AD group (FC \< 0.5, *p* \< 0.05).](dee-0009-0053-g01){#F1}

###### 

Participant characteristics and results of the general urinalysis

  -----------------------------------------------------------------------------------------------------------------------
                                                                 AD (*n* = 18)      Control (*n* = 18)        *p* value
  -------------------------------------------------------------- ------------------ ------------------------- -----------
  Age, years                                                     72.9±5.6           72.8±5.2                  0.951

  Males, *n*                                                     8                  8                         1.000

  MMSE points                                                    21.6±4.5           28.8±0.7                  \<0.001

  Urinary albumin[^a^](#T1F1){ref-type="table-fn"}, pg/mL        46.18±24.8 (11)    18.6±4.7 (10)             0.298

  Urinary creatinine, mg/dL                                      106.4±13.8         77.7±10.5                 0.107

  Albumin/creatinine[^b^](#T1F2){ref-type="table-fn"}, mg/gCr\   22.7±6.6           22.4±6.0                  0.976
  Results of the urine test strip                                                                             

  Urinary protein level                                          -- (17), ± (1)     -- (18)                   0.486

  Urinary blood level                                            \- (16), 2+ (28)   \- (14), 1+ (1), 3+ (1)   0.486

  Urinary glucose level                                          -- (17), 2+ (1)    \- (16), ± (1), 1+ (1)    0.019
  -----------------------------------------------------------------------------------------------------------------------

Results are presented as means ± SD for continuous variables. Values in parentheses are numbers of patients. *p* values were calculated using an unpaired *t* test and Fisher\'s exact test for continuous variables and categorical variables, respectively.

Undetectable (\<5 pg/mL) in 7 AD and 8 control group patients. The mean ± SD of urinary albumin was calculated from values of detected samples.

For calculation of this ratio, undetected albumin was substituted with 5 pg/mL.

###### 

List of 109 significantly increased or decreased proteins

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Accession No.   MW,\    Protein description (gene name)                                                     log~2~FC (AD/ control)   Mean SI~N~ value[^a^](#T2F1){ref-type="table-fn"}   Detected cases, *n*            Welch\'s*p* value   FDR         
                  kDa                                                                                                                                                                                                                                     
  --------------- ------- ----------------------------------------------------------------------------------- ------------------------ --------------------------------------------------- --------------------- -------- ------------------- ----------- -----------
  P02042          16.0    Hemoglobin subunitδ (HBD)                                                           −17.59                   0.0001                                              19.7571               0        10                  0.032       0.166

  Q8N2U0          11.7    Transmembrane protein 256 (TMEM256)                                                 −10.53                   0.0001                                              0.1478                0        9                   0.006       0.068

  A0AVF1          64.1    Intraflagellar transport protein 56 (TTC26)                                         −10.49                   0.0001                                              0.1440                0        12                  0.023       0.138

  P81605-2        12.4    Isoform 2 of dermcidin (DCD)                                                        −10.41                   0.0001                                              0.1360                0        13                  0.003       0.056

  **P06703**      10.2    **Protein S100-A6 (S100A6)**                                                        --**10.37**              **0.0001**                                          **0.1320**            **0**    **15**              **0.000**   **0.048**

  P54710          7.3     Sodium/potassium-transporting ATPase subunitγ(FXYD2)                                −10.20                   0.0001                                              0.1178                0        9                   0.004       0.058

  Q15485          34.0    Ficolin-2 (FCN2)                                                                    −9.99                    0.0001                                              0.1017                0        12                  0.002       0.050

  P20827          23.8    Ephrin-A1 (EFNA1)                                                                   −9.88                    0.0001                                              0.0941                0        10                  0.019       0.123

  P21926          25.4    CD9 antigen(CD9)                                                                    −9.73                    0.0001                                              0.0852                0        9                   0.007       0.070

  P01127          27.3    Platelet-derived growth factor subunit B (PDGFB)                                    −9.64                    0.0001                                              0.0796                0        9                   0.030       0.164

  **P02656**      10.8    **Apolipoprotein C-III (AP0C3)**                                                    --**9.63**               **0.0001**                                          **0.0793**            **0**    **12**              **0.000**   **0.048**

  000241          43.2    Signal-regulatory protein ß~1~ (SIRPB1)                                             −9.48                    0.0001                                              0.0714                0        12                  0.011       0.095

  P55259-3        59.1    Isoform a of pancreatic secretory granule membrane major glycoprotein GP            −9.47                    0.0001                                              0.0709                0        9                   0.009       0.081

  Q7LBR1          22.1    Charged multivesicular body protein 1b (CHMP1B)                                     −9.26                    0.0001                                              0.0612                0        13                  0.042       0.196

  Q6UXB4          32.5    C-type lectin domain family 4 member G (CLEC4G)                                     −9.17                    0.0001                                              0.0576                0        12                  0.008       0.077

  Q96PP9          73.1    Guanylate-binding protein 4 (GBP4)                                                  −9.10                    0.0001                                              0.0550                0        9                   0.017       0.114

  **P36915**      68.7    **Guanine nucleotide-binding protein-like 1 (GNL1)**                                **−9.05**                **0.0001**                                          **0.0532**            **0**    **10**              **0.002**   **0.048**

  P61981          28.3    14-3-3 protein γ(YWHAG)                                                             −8.87                    0.0001                                              0.0467                0        9                   0.022       0.135

  P09972          39.4    Fructose-bisphosphate aldolase C (ALDOC)                                            −8.57                    0.0001                                              0.0381                0        11                  0.015       0.110

  **Q6UY14-3**    118.7   **Isoform 3 of ADAMTS-like protein 4 (ADAMTSL4)**                                   --**8.52**               **0.0001**                                          **0.0366**            **0**    **14**              **0.001**   **0.048**

  **Q00796**      38.3    **Sorbitol dehydrogenase (SORD)**                                                   --**8.52**               **0.0001**                                          **0.0368**            **0**    **12**              **0.002**   **0.048**

  **000592**      58.6    **Podocalyxin (PODXL)**                                                             --**8.45**               **0.0001**                                          **0.0350**            **0**    **12**              **0.001**   **0.048**

  Q6FHJ7          39.8    Secreted frizzled-related protein 4 (SFRP4)                                         −8.45                    0.0001                                              0.0349                0        10                  0.012       0.099

  P02748          63.1    Complement component C9 (C9)                                                        −8.29                    0.0001                                              0.0313                0        10                  0.007       0.070

  **P08238**      83.2    **HSP 90-ß (HSP90AB1)**                                                             --**8.16**               **0.0001**                                          **0.0286**            **0**    **10**              **0.002**   **0.048**

  **Q9Y3B3**      25.2    **Transmembrane emp24 domain-containing protein 7 (TMED7)**                         --**8.15**               **0.0001**                                          **0.0284**            **0**    **9**               **0.002**   **0.048**

  014578          231.4   Citron p-interacting kinase (CIT)                                                   −7.86                    0.0001                                              0.0233                0        10                  0.009       0.079

  **P07711**      37.5    **Cathepsin L1 (CTSL)**                                                             --**7.84**               **0.0001**                                          **0.0229**            **0**    **10**              **0.002**   **0.048**

  P19823          106.4   Inter-a-trypsin inhibitor heavy chain H2 (ITIH2)                                    −7.60                    0.0001                                              0.0194                0        12                  0.025       0.145

  Q8IUL8          126.2   Cartilage intermediate layer protein 2 (CILP2)                                      −7.38                    0.0001                                              0.0166                0        10                  0.027       0.155

  **P16284**      82.5    **Platelet endothelial cell adhesion molecule (PECAM1)**                            --**6.46**               **0.0001**                                          **0.0088**            **0**    **10**              **0.002**   **0.048**

  P20774          33.9    Mimecan (0GN)                                                                       −6.43                    0.0001                                              0.0086                0        9                   0.016       0.111

  **Q9NPY3**      68.5    **Complement component C1q receptor (CD93)**                                        --**6.38**               **0.0001**                                          **0.0083**            **0**    **9**               **0.002**   **0.049**

  P16234          122.6   Platelet-derived growth factor receptor a (PDGFRA)                                  −5.75                    0.0001                                              0.0054                0        10                  0.004       0.058

  P25311          34.2    Zinc-a-2-glycoprotein (AZGP1)                                                       −2.15                    5.6354                                              25.0614               17       18                  0.007       0.072

  P00746          27.0    Complement factor D (CFD)                                                           −1.30                    0.0796                                              0.1959                9        13                  0.048       0.217

  Q9NQ84-2        49.4    Isoform 2 of G-protein coupled receptor family C group 5 member C (GPRC5C)          1.06                     0.2948                                              0.1411                18       18                  0.049       0.217

  Q6GTX8          31.4    Leukocyte-associated immunoglobulin-like receptor 1 (LAIR1)                         1.10                     3.4443                                              1.6068                18       18                  0.029       0.163

  P21810          41.6    Biglycan (BGN)                                                                      1.13                     0.1803                                              0.0822                15       17                  0.020       0.124

  P11047          177.5   Laminin subunit γ-1 (LAMC1)                                                         1.17                     0.0121                                              0.0054                16       12                  0.007       0.070

  P07602          58.1    Prosaposin (PSAP)                                                                   1.17                     0.3748                                              0.1664                18       18                  0.033       0.166

  P10643          93.5    Complement component C7 (C7)                                                        1.17                     4.3890                                              1.9449                18       18                  0.045       0.206

  P35241-5        71.0    Isoform 5 of radixin (RDX)                                                          1.26                     0.2582                                              0.1081                16       18                  0.022       0.134

  P33908          72.9    Mannosyl-oligosaccharide 1,2-α-mannosidase IA (MAN1A1)                              1.26                     0.1469                                              0.0611                13       10                  0.040       0.191

  P10253          105.3   Lysosomal α-glucosidase (GAA)                                                       1.27                     1.3006                                              0.5395                18       18                  0.016       0.111

  Q9H3G5          54.1    Probable serine carboxypeptidase CPVL (CPVL)                                        1.34                     0.2208                                              0.0870                15       11                  0.045       0.206

  P07686          63.1    Hexosaminidase subunit ß (HEXB)                                                     1.35                     0.1201                                              0.0472                15       12                  0.030       0.164

  Q12860          113.2   Contactin-1 (CNTN1)                                                                 1.37                     0.0319                                              0.0124                16       11                  0.032       0.166

  P0DJD8          42.0    Pepsin A-3 (PGA3)                                                                   1.51                     4.3450                                              1.5285                18       17                  0.017       0.114

  P06744-2        64.3    Isoform 2 of glucose-6-phosphate isom erase (API)                                   1.61                     0.0687                                              0.0224                14       11                  0.041       0.194

  Q16651          36.4    Protasis (PRSS8)                                                                    1.81                     0.8232                                              0.2355                18       18                  0.014       0.106

  P34059          58.0    N-acetylgalactosamine-6-sulfatase (GAINS)                                           1.90                     0.0533                                              0.0143                14       12                  0.021       0.132

  Q5JS37          38.3    NHL repeat-containing protein 3 (NHLRC3)                                            2.48                     0.0701                                              0.0126                12       10                  0.015       0.109

  Q5JRA6          213.6   Melanoma inhibitory activity protein 3 (MIA3)                                       5.09                     0.0034                                              0.0001                12       0                   0.007       0.070

  P13591          94.5    Neural cell adhesion molecule 1 (NCAM1)                                             5.60                     0.0048                                              0.0001                9        0                   0.006       0.065

  Q7Z7M0          302.9   Multiple epidermal growth factor-like domain protein 8 (MEGF8)                      5.61                     0.0049                                              0.0001                13       0                   0.003       0.056

  Q92859          159.9   Neogen-in (NE01)                                                                    5.69                     0.0052                                              0.0001                12       0                   0.003       0.052

  Q6UX71          59.5    Alexin domain-containing protein 2 (PLXDC2)                                         5.71                     0.0052                                              0.0001                11       0                   0.005       0.065

  Q9NZV1          113.7   Cysteine-rich motor neuron 1 protein (CRIM1)                                        5.88                     0.0059                                              0.0001                9        0                   0.005       0.065

  Q92563          46.7    Testican-2 (SP0CK2)                                                                 5.91                     0.0060                                              0.0001                12       0                   0.009       0.079

  **P08253**      73.8    **72-kDa type IV collagens\' (MMP2)**                                               **5.98**                 **0.0063**                                          **0.0001**            **10**   **0**               **0.001**   **0.048**

  Q15375          112.0   Ephrin type-A receptor 7 (EPHA7)                                                    6.05                     0.0066                                              0.0001                10       0                   0.005       0.063

  P16112          250.0   Aggrecan core protein (ACAN)                                                        6.18                     0.0072                                              0.0001                9        0                   0.037       0.179

  **P07357**      65.1    **Complement component C8 a chain (C8A)**                                           **6.29**                 **0.0078**                                          **0.0001**            **9**    **0**               **0.002**   **0.048**

  **Q92954**      151.0   **Proteoglycan 4 (PRG4)**                                                           **6.38**                 **0.0084**                                          **0.0001**            **11**   **0**               **0.001**   **0.048**

  Q66K79-2        72.5    Isoform 2 of carboxypeptidase Z (CPZ)                                               6.42                     0.0086                                              0.0001                9        0                   0.009       0.079

  O75787          39.0    Renin receptor (ATP6AP2)                                                            6.83                     0.0114                                              0.0001                9        0                   0.011       0.095

  O43405          59.4    Cochlin (COCH)                                                                      6.89                     0.0118                                              0.0001                9        0                   0.045       0.206

  O00622          42.0    Protein CYR61 (CYR61)                                                               6.95                     0.0124                                              0.0001                9        0                   0.006       0.065

  Q9UJ96          51.2    Potassium voltage-gated channel subfamily G member 2 (KCNG2)                        7.00                     0.0128                                              0.0001                9        0                   0.005       0.060

  P50897          34.2    Palmitoyl-protein thioesterase 1 (PPT1)                                             7.29                     0.0157                                              0.0001                9        0                   0.034       0.172

  **P55083-2**    31.1    **Isoform 2 of microfibril-associated glycoprotein 4 (MFAP4)**                      **7.32**                 **0.0159**                                          **0.0001**            **10**   **0**               **0.002**   **0.048**

  **O75309**      89.9    **Cadherin-16 (CDH16)**                                                             **7.33**                 **0.0161**                                          **0.0001**            **12**   **0**               **0.001**   **0.048**

  Q08345-5        101.7   Isoform 4 of epithelial discoidin domain-containing receptor 1\                     7.35                     0.0164                                              0.0001                10       0                   0.035       0.173
                          (DDR1)                                                                                                                                                                                                                          

  P35858-2        70.2    Isoform 2 of insulin-like growth factor-binding protein complex acid labile subun   7.40                     0.0169                                              0.0001                10       0                   0.003       0.056

  Q8NI32-2        23.3    Isoform 2 of Ly6/PLAUR domain-containing protein 6B (LYPD6B)                        7.57                     0.0189                                              0.0001                11       0                   0.024       0.142

  Q8N307          71.9    Mucin-20 (MUC20)                                                                    7.79                     0.0221                                              0.0001                11       0                   0.004       0.058

  **P55957-2**    26.8    **Isoform 2 of BH3-interacting domain death agonist (BID)**                         **8.22**                 **0.0299**                                          **0.0001**            **9**    **0**               **0.002**   **0.048**

  P34896          53.0    Serine hydroxymethyltransferase, cytosolic (SHMT1)                                  8.25                     0.0304                                              0.0001                12       0                   0.013       0.103

  Q6UX73          45.4    UPF0764 protein C16orf89 (C16orf89)                                                 8.37                     0.0332                                              0.0001                11       0                   0.031       0.164

  Q13145          29.1    BMP and act ivin membrane-bound inhibitor homolog (IAMBI)                           8.39                     0.0335                                              0.0001                9        0                   0.017       0.114

  Q8IV08          54.7    Phospholipase D3 (PLD3)                                                             8.47                     0.0355                                              0.0001                12       0                   0.032       0.166

  P17174          46.2    Aspartate aminotransferase, cytoplasmic (GOT1)                                      8.51                     0.0365                                              0.0001                9        0                   0.006       0.065

  P23526          47.7    Adenosylhomocysteinase (AHCY)                                                       8.57                     0.0381                                              0.0001                9        0                   0.012       0.098

  P00491          32.1    Purine nucleoside phosphorylase (PNP)                                               8.68                     0.0410                                              0.0001                9        0                   0.014       0.106

  **Q9BRK5**      41.8    **45-kDa calcium-binding protein (SDF4)**                                           **8.77**                 **0.0437**                                          **0.0001**            **14**   **0**               **0.001**   **0.048**

  P10092          13.7    Calcitonin gene-related peptide 2 (CALCB)                                           8.93                     0.0488                                              0.0001                10       0                   0.007       0.070

  Q9H444          24.9    Charged multivesicular body protein 4b (CHMP4B)                                     9.12                     0.0556                                              0.0001                12       0                   0.005       0.062

  **P15121**      35.8    **Aldose reductase (AKR1B1)**                                                       **9.13**                 **0.0559**                                          **0.0001**            **13**   **0**               **0.002**   **0.048**

  O95445          21.2    Apolipoprotein M (APOM)                                                             9.16                     0.0572                                              0.0001                10       0                   0.004       0.058

  P41181          28.8    Aquaporin-2 (AQP2)                                                                  9.19                     0.0585                                              0.0001                10       0                   0.006       0.065

  P01889          40.4    ALA class I histocompatibility antigen, B-7 a chain (ALA-\$)                        9.30                     0.0631                                              0.0001                11       0                   0.002       0.050

  P60953          21.2    Cell division control protein 42 homolog (CDC42)                                    9.37                     0.0660                                              0.0001                9        0                   0.023       0.138

  **P78380**      30.9    **Oxidized low-density lipoprotein receptor 1 (OLR1)**                              **9.39**                 **0.0670**                                          **0.0001**            **12**   **0**               **0.001**   **0.048**

  P17050          46.5    α-N-acetylgalactosaminidase (NAGA)                                                  9.47                     0.0709                                              0.0001                12       0                   0.016       0.111

  **P17936-2**    32.2    **Isoform 2 of insulin-like growth factor-binding protein 3 (IGFBP3)**              **9.49**                 **0.0720**                                          **0.0001**            **11**   **0**               **0.001**   **0.048**

  P62873          37.4    Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit ß-1 (GNB1)                9.65                     0.0801                                              0.0001                11       0                   0.004       0.058

  **P16152**      30.4    **Carbonyl reductase (NADPH) 1 (CBR1)**                                             **9.82**                 **0.0903**                                          **0.0001**            **11**   **0**               **0.001**   **0.048**

  P49441          44.0    Inositol polyphosphate 1-phosphatase (INPP1)                                        9.85                     0.0921                                              0.0001                9        0                   0.009       0.079

  P15153          21.4    Ras-related C3 botulinum toxin substrate 2 (RAC2)                                   9.88                     0.0942                                              0.0001                12       0                   0.002       0.050

  **P29622**      48.5    **Kallistatin (SERPINA4)**                                                          **10.00**                **0.1021**                                          **0.0001**            **13**   **0**               **0.001**   **0.048**

  P18669          28.8    Phosphoglycerate mutase 1 (PGAM1)                                                   10.02                    0.1038                                              0.0001                10       0                   0.004       0.058

  P31944          27.7    Caspase-14 (CASP14)                                                                 10.56                    0.1510                                              0.0001                9        0                   0.031       0.164

  P10599          11.7    Thioredoxin (TXN)                                                                   10.64                    0.1599                                              0.0001                10       0                   0.008       0.073

  P01225          14.7    Follitropin subunit p (FSHB)                                                        10.82                    0.1804                                              0.0001                9        0                   0.019       0.121

  P62979          18.0    Ubiquitin-40S ribosomal protein S27a (RPS27A)                                       11.22                    0.2393                                              0.0001                9        0                   0.004       0.058

  Q07654          8.6     Trefoil factor 3 (TFF3)                                                             12.02                    0.4156                                              0.0001                12       0                   0.005       0.060

  P04155          9.1     Trefoil factor 1 (TFF1)                                                             12.95                    0.7906                                              0.0001                13       0                   0.004       0.058

  **P06312**      13.4    **Ig**κ**chain V-IV region (fragment) (IGKV4-1)**                                   **15.80**                **5.6997**                                          **0.0001**            **12**   **0**               **0.001**   **0.048**
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Bold text corresponds to proteins that remained significant after FDR correction. MW, molecular weight; FDR, false discovery rate.

Proteins not identified in certain samples were assumed to be at levels under the detection limit and thus were assigned a value that was half of the minimum SIn value (i.e., 0.0001).

###### 

Significantly enriched annotation clusters of significantly increased or decreased proteins (FC \>2 or \<0.5, *p* \< 0.05) calculated by DAVID Bioinformatics Resources 6.8

  -------------------------------------------------------------------------------------------------------------
  Term                                                     *p* value   Enrichment\   Gene names
                                                                       score         
  -------------------------------------------------------- ----------- ------------- --------------------------
  *Cluster 1*                                                                        

  G0:0043202\~lysosomal lumen                              \<0.001     4.25          PSAP, PPT1, OGN, GAA,

  hsa04142:lysosome                                        \<0.001                   GALNS, BGN, HEXB, ACAN,

  G0:0005764\~lysosome                                     0.011                     NAGA, CTSL, GOT1

                                                                                     

  *Cluster 2*                                                                        

  G0:0006957\~complement activation, alternative pathway   \<0.001     2.38          LAMC1, C7, C8A, IGKV4-1,

  hsa05020: Prion diseases                                 \<0.001                   PNP, FCN2, C9, HLA-B,

  G0:0005579\~membrane attack complex                      0.001                     ITIH2, PRG4, HBD, NCAM1,

  G0:0006956\~complement activation                        0.002                     CFD

  G0:0072562\~blood microparticle                          0.002                     

  G0:0030449\~regulation of complement activation          0.014                     

  hsa04610: complement and coagulation cascades            0.018                     

  G0:0006958\~complement activation, classical pathway     0.022                     

  G0:0006955\~immune response                              0.042                     

  hsa05322: systemic lupus erythematosus                   0.296                     

                                                                                     

  *Cluster 3*                                                                        

  G0:0006094-gluconeogenesis                               0.002       1.7           PGAM1, ALDOC, SHMT1,

  G0:0061621-canonical glycolysis                          0.011                     GPI, GOT1

  hsa01200: carbon metabolism                              0.013                     

  G0:0006096-glycolytic process                            0.018                     

  hsa01230: biosynthesis of amino acids                    0.022                     

  hsa01130: biosynthesis of antibiotics                    0.092                     

  hsa00010: glycolysis/gluconeogenesis                     0.102                     
  -------------------------------------------------------------------------------------------------------------

###### 

List of the top 5 pathways contributing to the interrelation network and the AD-related network calculated by KeyMolnet

  Rank                                              Pathway                              Score
  ------------------------------------------------- ------------------------------------ --------
  *Top 5 pathways from the interrelation network*                                        
  1                                                 HSP90 signaling pathway              103.42
  2                                                 Lipoprotein metabolism               86.74
  3                                                 Redox regulation by thioredoxin      53.19
  4                                                 MMP signaling pathway                45.63
  5                                                 Tetraspanin signaling pathway        45.32
                                                                                         
  *Top 5 pathways from the AD-related network*                                           
  1                                                 Lipoprotein metabolism               90.35
  2                                                 Transcriptional regulation by CREB   88.81
  3                                                 HSP90 signaling pathway              57.46
  4                                                 MMP signaling pathway                47.19
  5                                                 Redox regulation by thioredoxin      44.02

[^1]: Y.W. and Y.H. contributed equally to this work.
